iBio Inc. | Cash Flow

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
6,198.00
3,666.00
6,625.00
10,657.00
16,139.00
16,108
Depreciation, Depletion & Amortization
338.00
361.00
363.00
940.00
1,676.00
1,709
Other Funds
-
-
-
15,000.00
-
831
Funds from Operations
5,114.00
4,036.00
5,300.00
8,439.00
13,453.00
13,568
Changes in Working Capital
265.00
80.00
575.00
367.00
290.00
88
Net Operating Cash Flow
4,849.00
4,116.00
4,725.00
8,072.00
13,163.00
13,480
Capital Expenditures
195.00
259.00
215.00
68.00
1,593.00
Net Investing Cash Flow
195.00
259.00
215.00
68.00
1,593.00
Issuance/Reduction of Debt, Net
-
-
-
565.00
170.00
Net Financing Cash Flow
3,834.00
3,551.00
10,867.00
21,664.00
170.00
Net Change in Cash
1,210.00
824.00
5,904.00
13,520.00
14,926.00
Free Cash Flow
4,856.00
4,120.00
4,738.00
8,140.00
14,486.00
Change in Capital Stock
3,834.00
3,551.00
10,867.00
7,229.00
-
Exchange Rate Effect
-
-
23.00
4.00
-

About iBio

View Profile
Address
600 Madison Avenue
New York New York 10022
United States
Employees -
Website http://www.ibioinc.com
Updated 07/08/2019
iBio, Inc. operates as a biotechnology company, which focuses on using its proprietary technologies and production facilities to provide product development and manufacturing services to clients, collaborators, and third-party customers as well as developing and commercializing its own product candidates. It operates through the iBio, Inc. and iBio CDMO business segments. The iBio CDMO segment is a subsidiary of the company, which develops and manufactures plant-made pharmaceuticals.